Ceregate receives financing
Following a breakthrough in the clinical development of brain stimulation, Ceregate is able to attract new investors. The amount of the investment is not known.
Ceregate's current financing round is led by new investors 468 Capital and Re.mind Capital. This means that the start-up has investors on board who are experienced in the fields of deep technology and mental health. The existing investors TruVenturo, Heal Capital and High-Tech Gründerfonds were also involved in the financing round.
The additional capital will be used to expand the team and further develop the platform. "We are very excited because this means that several applications of our technology that can provide real clinical solutions for patients are only 1-2 years away," says founder and CEO Bálint Várkuti.
The start-up has developed a computer-brain interface platform that transmits information to the human brain and can therefore be used for neuromodulation therapy. The treatment is intended to help patients with neurological or sensory deficits. The aim of Ceregate is to increase patients' independence and improve their quality of life.
Newsletter
Startups, stories and stats from the German startup ecosystem straight to your inbox. Subscribe with 2 clicks. Noice.
LinkedIn ConnectFYI: English edition available
Hello my friend, have you been stranded on the German edition of Startbase? At least your browser tells us, that you do not speak German - so maybe you would like to switch to the English edition instead?
FYI: Deutsche Edition verfügbar
Hallo mein Freund, du befindest dich auf der Englischen Edition der Startbase und laut deinem Browser sprichst du eigentlich auch Deutsch. Magst du die Sprache wechseln?
